Biotech Daily Market Report September 25, 2006
September 25th 2006 12:37
ASX UP, BIOTECHS MIXED:
NOVOGEN UP 9%, BIOTA UP 8%
NOVOGEN UP 9%, BIOTA UP 8%
THE MARKET
The Australian stock market closed up 0.09 percent on Monday September 25, 2006, with the All Ordinaries edging up 4.5 points to 4,952.9 points. Fourteen of the Biotech Daily Top 40 stocks were up, 16 stocks fell, six traded unchanged and four were untraded. Ten of the Top 20 rose and nine fell, while four of the Second 20 rose and seven fell.
Novogen was best, up 23 cents or 8.52 percent to $2.93 on moderate volumes, followed by Biota up 9.5 cents or 8.26 percent to $1.245 with 985,548 shares traded on unconfirmed rumors of major Canadian order for Relenza. Phosphagenics, Phylogica and Progen were all up more than five percent; Avexa and Psivida climbed more than four percent; Mesoblast was up 3.39 percent; CSL. Evogenix and Metabolic were up more than two percent; with Ventracor up 1.99 percent.
Clinical Cell, Optiscan, Peplin and Polartechnics all fell between 4.0 and 4.5 percent; Bionomics, Chemgenex, Neuren and Portland fell more than three percent; Acrux, Biosignal, Proteome and Sirtex lost more than two percent; with Pharmaxis and Prima slipping more than one percent.
TODAY'S NEWS
* PROF PAUL ZIMMET ‘AMAZED’ AT APOLLO’S ORAL INSULIN
* PHOSPHAGENICS GTP0805 ENHANCES BREAST CANCER DRUG
* PEPTECH’S 12-MONTH DOG CONTRACEPTIVE APPROVED
* USCOM HEART MONITOR VALIDATED AGAINST ALTERNATIVES
* FIRST US HIP IMPLANTS FOR PORTLAND
* BONE PLACEMENT RAISES $1.8m
* QUALITY ISSUES DELAY RITRACT SHIPMENT
* VENTRACOR AGM TO ISSUE MD PETER CROSBY 4m RIGHTS
* PHARMAXIS DOUBLES DIRECTORS FEES POOL TO $600,000
* BENITEC TO MELBOURNE; APPOINTS PAUL MCMAHON CFO
* HOSPIRA HAS 82.5% OF BRESAGEN
* EDITORIAL: DIRECTORS’ FEES AND FINANCIAL REPORTING
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 29 |
| Vote |
Add To: 
subscribe to this blog